RxDoctor Payments Data

Carley Lueken, APRN

Family · Springdale, ARNPI 1942963327

Payments from drug & device makers

$431in general payments, 2019–2025

Across 28 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$131
  • Boehringer Ingelheim$131
  • AstraZeneca$53
  • Lilly USA, LLC$27
  • Dexcom, Inc.$25
  • Bayer$17
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$431100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$431 in reported general payments places this provider in the 50th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$533
Medicare patients
13
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin65$49,527
Synjardy XrEmpagliflozin/Metformin Hcl56$33,037
FarxigaDapagliflozin Propanediol33$31,505
JanumetSitagliptin Phos/Metformin Hcl26$20,531
Tresiba Flextouch U-200Insulin Degludec11$19,808
TrulicityDulaglutide18$16,684
RybelsusSemaglutide18$15,677
OzempicSemaglutide15$14,832
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$11,656
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$10,349
Xigduo XrDapaglifloz Propaned/Metformin12$9,756
JanuviaSitagliptin Phosphate11$8,858
SymbicortBudesonide/Formoterol Fumarate15$3,140
LantusInsulin Glargine,hum.Rec.Anlog25$3,137
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$131$82,564121 claims
AstraZenecaFarxiga, Symbicort$53$34,64648 claims
MerckJanumet, Januvia$12$29,39037 claims
Lilly USA, LLCTrulicity$27$16,68418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,103 family providers in Arkansas.

Other family in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →